cytarabine has been researched along with ondansetron in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (31.58) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Carden, PA; Ekert, H; Mitchell, SL; Tiedemann, K; Waters, KD | 1 |
| Richardson, BC; Yung, RL | 1 |
| Chavez, CM; Duncan, MH; Holdsworth, MT; Leasure, MM; Raisch, DW | 1 |
| Fox, JL; King, DT; Stewart, JT; Warren, FW | 1 |
| Sundström, GM; Wahlin, A | 1 |
| Chavez, CM; Holdsworth, MT; Raisch, DW; Winter, SS | 1 |
| Klener, P; Procházka, B; Slabý, J; Trnený, M | 1 |
| Atlas, MP; Giugliano, DM; Mahan, RA; Parker, RI; Prakash, D | 1 |
| Pinsk, M; Turner, SR | 1 |
| Bekele, BN; Blamble, DA; Borthakur, G; Cabanillas, M; Cortes, JE; Kantarjian, H; Mattiuzzi, GN; O'Brien, S; Xiao, L | 1 |
| Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A | 1 |
| He, H; Li, X; Li, XP; Li, Y; Liu, ZG; Liu, ZQ; Wang, Y; Xu, YJ; Yin, JY; Zhai, M; Zhang, Y; Zhou, F; Zhou, HH | 1 |
| Badar, T; Borthakur, G; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, H; Mattiuzzi, G; O'Brien, S; Poku, R; Wierda, W | 1 |
| Andrick, B; Clemmons, AB; DeRemer, D; Gandhi, A; Orr, J; Sportes, C | 1 |
| Lertvivatpong, N; Monsereenusorn, C; Photia, A; Rujkijyanont, P; Ruktrirong, J; Traivaree, C | 1 |
1 review(s) available for cytarabine and ondansetron
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
9 trial(s) available for cytarabine and ondansetron
| Article | Year |
|---|---|
Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia.
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Drug Evaluation; Female; Humans; Imidazoles; Injections, Intravenous; Liver Function Tests; Male; Ondansetron; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Serotonin Antagonists; Vomiting | 1990 |
Comparison of efficacies of ondansetron and dixyrazine for prophylaxis of emesis during induction treatment in acute myelogenous leukemia. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Amsacrine; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Ondansetron; Phenothiazines; Pilot Projects; Serotonin Antagonists; Vomiting | 1997 |
Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Granisetron; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lymphoma; Male; Melphalan; Nausea; Ondansetron; Serotonin Antagonists; Transplantation, Autologous; Tropisetron; Vomiting | 2000 |
Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cross-Over Studies; Cytarabine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Headache; Humans; Hydrocortisone; Injections, Intravenous; Leukemia; Male; Mercaptopurine; Methotrexate; Nausea; Ondansetron; Risk; Serotonin Antagonists; Treatment Outcome; Vincristine; Vomiting | 2001 |
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Isoquinolines; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2010 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Melphalan; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Transplantation, Autologous; Treatment Outcome; Vomiting | 2011 |
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytara
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cytarabine; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Treatment Outcome; Vomiting | 2015 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Melphalan; Middle Aged; Morpholines; Nausea; Olanzapine; Ondansetron; Podophyllotoxin; Vomiting | 2018 |
Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: A comparative randomized double-blind controlled trial.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Double-Blind Method; Female; Hematologic Neoplasms; Humans; Hydrocortisone; Infant; Infant, Newborn; Male; Methotrexate; Nausea; Ondansetron; Prospective Studies; Vomiting | 2021 |
9 other study(ies) available for cytarabine and ondansetron
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Cytarabine therapy for refractory cutaneous lupus.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Drug Therapy, Combination; Female; Humans; Lupus Erythematosus, Cutaneous; Ondansetron | 1995 |
Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Etoposide; Female; Humans; Infusions, Intravenous; Male; Nausea; Ondansetron; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Severity of Illness Index; Vomiting | 1995 |
Stability of ondansetron hydrochloride and five antineoplastic medications.
Topics: Antiemetics; Antineoplastic Agents; Cytarabine; Dacarbazine; Doxorubicin; Drug Stability; Ondansetron | 1996 |
Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Hydrocortisone; Injections, Spinal; Male; Methotrexate; Nausea; Ondansetron; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 1998 |
Ondansetron-associated hypokalemia in a 2-year-old with pre-B-cell ALL.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Cytarabine; Dexamethasone; Female; Humans; Hypokalemia; Mercaptopurine; Methotrexate; Nausea; Ondansetron; Polyethylene Glycols; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Vincristine | 2008 |
Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Alleles; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cytarabine; Cytochrome P-450 CYP2D6; Drug Resistance; Female; Haplotypes; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Ondansetron; Polymorphism, Single Nucleotide; Vomiting; Young Adult | 2014 |